San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor in the weight loss drug current market in February right after revealing promising knowledge from a mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in March